Central Sensitization and Nociplastic Pain

Table of Contents

  1. What Central Sensitization Actually Is
  2. Wind-Up, NMDA, and Temporal Summation
  3. Long-Term Potentiation of Pain Synapses
  4. Allodynia and Hyperalgesia — The Tell-Tale Signs
  5. Lost Brakes: Descending Inhibition and CPM
  6. Glia, Microglia, and Neuroinflammation
  7. Conditions Driven by Central Sensitization
  8. Measuring It: CSI and Quantitative Sensory Testing
  9. What the Brain Scans Show
  10. Treatment 1 — Pain Neuroscience Education and Graded Exposure
  11. Treatment 2 — Medications That Calm the System
  12. Treatment 3 — Aerobic Exercise and Sleep Repair
  13. What Recovery Actually Looks Like
  14. Key Research Papers
  15. Research Papers
  16. Connections

What Central Sensitization Actually Is

If you have been told your pain is "real but not from tissue damage," or that imaging keeps coming back unremarkable while you feel like you are on fire, you have probably run into the concept of central sensitization. This is not a vague hand-wave. It is a specific, well-documented change in how your spinal cord and brain process signals. The International Association for the Study of Pain (IASP) gave this kind of pain its own name in 2017: nociplastic pain. It sits alongside the two older categories — nociceptive pain (tissue injury) and neuropathic pain (nerve injury) — as a third mechanism.

The short version: your nervous system has learned to amplify danger signals. Inputs that used to be ignored or filtered out now get forwarded to conscious awareness as pain. Inputs that used to be mildly uncomfortable now feel excruciating. The hardware is intact. The software is cranked to maximum gain.

This matters because the treatments that work for a pulled muscle or a pinched nerve usually do not work here. No amount of anti-inflammatory medication fixes a volume knob that is stuck on eleven. You need different strategies — ones that target the processing itself.

Wind-Up, NMDA, and Temporal Summation

The foundational phenomenon in central sensitization is called wind-up, first described by Lorne Mendell and Patrick Wall in the 1960s. Here is how it works.

When a C-fiber (a small, slow pain nerve) fires repeatedly at a steady intensity — say, once per second — the second-order neuron in the dorsal horn of your spinal cord does not just respond steadily. Its response grows with each pulse. The tenth identical input produces a far larger signal than the first. This is temporal summation.

The molecular culprit is the NMDA receptor. Under normal conditions, NMDA receptors in the dorsal horn are plugged by a magnesium ion and largely silent. Ordinary pain signaling runs through AMPA receptors. But if C-fibers fire fast enough and long enough, the neuron depolarizes strongly enough to kick the magnesium out of the NMDA channel. Calcium floods in. Signaling cascades switch on. The neuron becomes hyper-responsive — not just for the duration of the input but for minutes, hours, and eventually, if the barrage continues, for months or years.

This is why chronic pain states often begin with a legitimate injury — surgery, a car accident, an infection, a bout of shingles — that lasts long enough to wind the spinal cord up. By the time the original tissue heals, the dorsal horn is stuck in amplification mode. The pain persists without the injury.

Long-Term Potentiation of Pain Synapses

Wind-up is the acute version. The chronic version borrows its machinery from the same brain system that stores memories: long-term potentiation (LTP). Pain-carrying synapses in the dorsal horn can undergo the same strengthening that happens when you learn a phone number or a piano piece. Once LTP sets in, the synapse is physically remodeled — more receptors, stronger connections, faster signaling.

In other words, your spinal cord has learned to be in pain. The learning is involuntary and nobody chose it, but it is a genuine form of neural plasticity. The good news hidden inside this grim fact: plasticity runs in both directions. What was learned can, with effort, be unlearned. That is the entire premise behind modern nociplastic-pain treatment.

Allodynia and Hyperalgesia — The Tell-Tale Signs

Two words describe the clinical face of central sensitization, and if you learn to recognize them in your own experience you will understand what your nervous system is doing.

Both can be primary (at the original injury site) or secondary (spreading outward into uninjured skin). Secondary hyperalgesia — a ring of tenderness around a wound, or tender spots far from any obvious cause — is the clearest clinical fingerprint of central sensitization. The original nerves in those tender zones are perfectly healthy. The spinal cord is the problem.

Other features that point toward a centralized pain picture:

Lost Brakes: Descending Inhibition and CPM

Your brain has a pain-damping system built in. Nuclei in the brainstem — the periaqueductal gray, the rostral ventromedial medulla, and the locus coeruleus — send fibers down the spinal cord that release serotonin, noradrenaline, and endogenous opioids onto dorsal-horn neurons. This is the descending inhibitory system. In healthy people, it filters a constant stream of noise out of the pain signal before it ever reaches consciousness.

In chronic nociplastic pain, these brakes fail. The classic way to test this in a clinic is a conditioned pain modulation (CPM) protocol, historically called diffuse noxious inhibitory control (DNIC). The examiner applies a mildly painful stimulus (say, a pressure on your thumb) and measures your threshold. Then they add a second, stronger noxious stimulus somewhere else on the body (often a cold-water bath for the other hand). In a healthy nervous system, the distant pain raises your thumb threshold — pain inhibits pain. In fibromyalgia, chronic low back pain, and many other central-sensitization states, CPM is weak or absent. The brakes are gone.

This finding matters practically because a medication that acts on descending inhibition — a serotonin-noradrenaline reuptake inhibitor such as duloxetine — is working at exactly the system that has failed. You are putting the brakes back in.

Glia, Microglia, and Neuroinflammation

For most of the twentieth century, pain research was a story about neurons. The last twenty years have rewritten the story. The glial cells — microglia, astrocytes — that were thought to be passive scaffolding turn out to be active participants.

When a nerve injury or prolonged nociceptive barrage hits the spinal cord, microglia switch on. They change shape, multiply, and start dumping inflammatory cytokines (IL-1 beta, TNF-alpha, IL-6) and chemokines into the synaptic cleft. These substances lower the firing threshold of nearby pain neurons, pull glutamate receptors to the surface, and strip away the mechanisms that normally shut signaling off. Astrocytes follow, often with a slower but longer-lasting inflammatory response.

This is why chronic pain has an inflammatory signature even when nothing in the peripheral tissue is inflamed. The inflammation is in the central nervous system itself — a process sometimes called neuroinflammation. It is also why drugs that target glial activation, such as low-dose naltrexone (LDN, typically 1.5–4.5 mg at bedtime), can produce pain relief that makes no sense if you are thinking only about neurons. LDN is believed to work in part by blocking toll-like receptor 4 (TLR4) on microglia, quieting the glial contribution to the sensitized state.

Conditions Driven by Central Sensitization

Once you have the framework, a long list of otherwise puzzling syndromes makes sense. They are not random. They share a mechanism.

This is not a diagnosis of exclusion and it is not code for "we give up." It is a positive, mechanism-based label that points to specific treatments.

Measuring It: CSI and Quantitative Sensory Testing

Two tools are most commonly used to quantify central sensitization in clinic and research.

The Central Sensitization Inventory (CSI). A 25-item self-report questionnaire validated by Neblett and colleagues. Each item asks how often you experience symptoms such as widespread pain, fatigue, non-restorative sleep, heightened sensitivity to light or sound, jaw pain, memory problems, restless legs, and stress-triggered flare-ups. Scores range 0–100. Cutoffs:

A score above 40 on the CSI — particularly in someone with widespread pain and normal imaging — is a strong signal that central sensitization is a driver of the clinical picture. It does not replace a clinical evaluation, but it gives you and your clinician a number to track over time.

Quantitative sensory testing (QST). A structured set of bedside tests that a trained provider (often a physical therapist or pain specialist) can run in about thirty minutes. Typical components:

QST is not available at every clinic, but academic pain centers and many research-oriented physical-therapy practices offer it. You do not need a positive QST to get treatment, but it can be useful for patients whose pain has been dismissed — it provides objective evidence that something is wrong with how the nervous system processes input.

What the Brain Scans Show

Functional MRI and related imaging have mapped central sensitization onto specific brain networks. You will not get this imaging clinically — it is research-grade — but knowing what it shows helps you understand your own experience.

The crucial point: none of these findings means your pain is "in your head" in the dismissive sense. The changes are physical, measurable, and located in the same nervous system that registers every other bodily signal. Pain is always a brain output, whether the driver is a broken bone or a sensitized dorsal horn.

Treatment 1 — Pain Neuroscience Education and Graded Exposure

The single most well-evidenced intervention for nociplastic pain is, counter-intuitively, education. Not the "drink more water and stretch" kind. Pain Neuroscience Education (PNE, sometimes called Explain Pain) teaches patients the biology of central sensitization — NMDA wind-up, glial activation, failed descending inhibition, LTP. The working premise: understanding that your nervous system has learned to amplify danger signals, and that learning can be unlearned, measurably reduces pain and disability.

Randomized trials — including work by Louw, Moseley, and Butler — show that PNE plus physiotherapy produces larger improvements in pain, disability, catastrophizing, and fear-avoidance than physiotherapy alone, and the effects persist at one-year follow-up. This article itself is, in a small way, doing PNE.

Once you understand the mechanism, the behavioral corollary is graded exposure — gradually and systematically returning to movements and activities that have become pain-associated. A classic fear-avoidance cycle: bending hurt once, so bending became scary, so bending was avoided, so the nervous system flagged bending as dangerous, so bending hurt more when tried. Graded exposure reverses this in tiny, planned increments. The body learns that bending is safe. The sensitized system turns its volume down.

This is the foundation for a family of modern talk-based therapies, including Pain Reprocessing Therapy and PNE. The Boulder Back Pain Study (Ashar et al., 2022) found that two-thirds of chronic back pain patients treated with PRT were pain-free or nearly pain-free at follow-up — a result unheard of in chronic pain.

Treatment 2 — Medications That Calm the System

Medications that work in nociplastic pain target the specific mechanisms above. None are miracle drugs. Expect roughly 30% pain reduction in roughly 30% of people — worth trying, worth stopping if no benefit appears in eight to twelve weeks.

What does not work well in pure nociplastic pain: NSAIDs, acetaminophen beyond minor benefit, and chronic opioids. Opioids are particularly risky in this population because they can induce their own form of central sensitization (opioid-induced hyperalgesia), worsening the underlying problem. See opioids for chronic non-cancer pain for the full discussion.

Treatment 3 — Aerobic Exercise and Sleep Repair

Two non-drug interventions have the best evidence base in nociplastic pain, and they are both hard to do when you feel terrible.

Graded aerobic exercise. In fibromyalgia and chronic widespread pain, aerobic training — walking, cycling, swimming, water aerobics — performed at moderate intensity for 20–30 minutes, three to five days a week, reliably reduces pain and improves function. The key word is graded. Start at a level you can sustain today without a flare tomorrow, hold it for two weeks, then add 10%. If you crash, step back to the last tolerated level and hold there longer. Many patients need to start at five minutes of slow walking. That is fine. The goal is to teach the nervous system that movement is safe, and the dose that accomplishes this grows over months. See sleep, exercise, and lifestyle.

Sleep repair. Non-restorative sleep is both a symptom of central sensitization and a driver of it. A single night of disrupted sleep measurably lowers pain thresholds in healthy controls the next day. Chronic sleep fragmentation inflames microglia and feeds the sensitization loop. Practical priorities, in order of impact:

Cognitive behavioral therapy for insomnia (CBT-I) is more effective than any sleeping pill and does not lose effect over time. Most major U.S. cities now have CBT-I providers, and several free apps (CBT-i Coach from the VA, for example) deliver the program.

What Recovery Actually Looks Like

Recovery from central sensitization is not a linear curve. It is a series of two-steps-forward, one-step-back oscillations over months to years. A few realistic points that most patients wish they had been told early:

Key Research Papers

Research Papers

For further reading, these PubMed topic searches return current peer-reviewed work on the mechanisms and management of central sensitization and nociplastic pain:

  1. Central sensitization and chronic pain
  2. Nociplastic pain — clinical criteria and mechanisms
  3. NMDA wind-up and dorsal-horn temporal summation
  4. Conditioned pain modulation in fibromyalgia
  5. Microglia, neuroinflammation, and chronic pain
  6. Central Sensitization Inventory validation studies
  7. Pain neuroscience education outcomes
  8. Low-dose naltrexone in fibromyalgia
  9. Duloxetine and milnacipran in centralized pain
  10. Default mode network and chronic pain

Connections

Back to Table of Contents